Skip to main content
. 2022 Sep 9;10(3):e36754. doi: 10.2196/36754

Table 1.

Characteristics of the studies and populations (N=16).

Study, year Country Publication type RCTa type Sample size Age, mean (SD) Male participants, n (%) MMSEb score Health condition Setting
Finn and McDonald [31], 2015 Australia Journal article Parallel 31 75.6 22 (71) 28.1 MCIc Clinical
Robert et al [32], 2020 France Journal article Parallel 46 79.4 22 (47.8) 21.4 Neurocognitive disorders Clinical
Savulich et al [33], 2017 United Kingdom Journal article Parallel 42 76.1 25 (59.5) 26.7 MCI Clinical
Valdes et al [34], 2012 United States Journal article Parallel 195 77.7 65 (33.3) NRd MCI Clinical
Yang and Kwak [35], 2017 South Korea Journal article Parallel 20 71 14 (70) 23.1 ADe Clinical
Thapa et al [36], 2020 South Korea Journal article Parallel 68 72.7 16 (23.5) 26.2 MCI Clinical
Tarnanas et al [37], 2014 Greece Book chapter Parallel 114 70.3 44 (39) 26.4 MCI Clinical
Fiatarone Singh et al [38], 2014 Australia Journal article Factorial 100 70.1 32 (32) 27 MCI Community
Amjad et al [39], 2019 Pakistan Journal article Parallel 44 NR NR 24 MCI Clinical
Wiloth et al [40], 2017 Germany Journal article Parallel 99 82.9 28 (28.3) 22 Dementia Clinical and community
Van Santen et al [41], 2020 Netherlands Journal article Cluster 112 79 60 (53.5) 18.6 Dementia Clinical
Karssemeijer et al [42], 2019 Netherlands Journal article Parallel 115 79.9 62 (53.9) 22.4 Dementia Clinical and community
Liao et al [43], 2021 Taiwan Journal article Parallel 61 81.5 20 (32.6) 22.9 MCI Community
Flak et al [44], 2019 Norway Journal article Parallel 85 66 57 (66.7) NR MCI Clinical
Hyer et al [45], 2016 United States Journal article Parallel 68 75.2 32 (47.1) 26 MCI Community
Park and Park [46], 2017 South Korea Journal article Parallel 78 67.3 42 (53.8) 26.5 MCI Community

aRCT: randomized controlled trial.

bMMSE: Mini-Mental State Examination.

cMCI: mild cognitive impairment.

dNR: not reported.

eAD: Alzheimer disease.